Mesoblast (NASDAQ:MESO – Get Free Report) and bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Analyst Recommendations
This is a breakdown of current recommendations for Mesoblast and bioAffinity Technologies, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Mesoblast | 0 | 1 | 2 | 1 | 3.00 |
bioAffinity Technologies | 0 | 1 | 0 | 0 | 2.00 |
Mesoblast currently has a consensus target price of $18.00, suggesting a potential upside of 18.66%. Given Mesoblast’s stronger consensus rating and higher probable upside, research analysts clearly believe Mesoblast is more favorable than bioAffinity Technologies.
Insider and Institutional Ownership
Volatility and Risk
Mesoblast has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 2.53, indicating that its stock price is 153% more volatile than the S&P 500.
Profitability
This table compares Mesoblast and bioAffinity Technologies’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Mesoblast | N/A | N/A | N/A |
bioAffinity Technologies | -110.53% | -367.64% | -154.15% |
Earnings and Valuation
This table compares Mesoblast and bioAffinity Technologies”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Mesoblast | $5.90 million | 329.11 | -$87.96 million | N/A | N/A |
bioAffinity Technologies | $9.36 million | 0.89 | -$9.04 million | ($0.72) | -0.41 |
bioAffinity Technologies has higher revenue and earnings than Mesoblast.
Summary
Mesoblast beats bioAffinity Technologies on 9 of the 13 factors compared between the two stocks.
About Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and GrĂ¼nenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.